217 completed. 217 Phase 3, 10 Phase 2.
By phase and status
Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis
Trials (filtered) newest first · largest first
All 217 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) Dupilumab, Placebo - Lichen Simplex Chronicus | Phase 3 | Completed | 142 | 2024-11-28 | 2026-09-11 |
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) Dupilumab, Placebo - Lichen Simplex Chronicus | Phase 3 | Completed | 138 | 2024-11-25 | 2026-09-11 |
Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis Roflumilast Cream 0.15%, Vehicle cream - Atopic Dermatitis (AD) | Phase 3 | Completed | 354 | 2024-11-21 | 2025-09-02 |
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis TQH2722 injection, Placebo of TQH2722 injection - Atopic Dermatitis | Phase 3 | Completed | 500 | 2024-10-08 | 2026-11-09 |
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis 611, Placebo, Topical corticosteroid - Dermatitis, Atopic, Eczema, Atopic | Phase 3 | Completed | 417 | 2024-09-23 | 2026-09-17 |
A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis SIM0718 Injection - Atopic Dermatitis | Phase 3 | Completed | 259 | 2024-07-04 | 2026-03-31 |
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis Lebrikizumab Pen - Atopic Dermatitis | Phase 3 | Completed | 55 | 2024-06-04 | 2025-07-29 |
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis Ruxolitinib Cream, Vehicle Cream - Atopic Dermatitis | Phase 3 | Completed | 241 | 2024-04-26 | 2026-10-15 |
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis Placebo, Lebrikizumab, Topical Corticosteroid - Atopic Dermatitis | Phase 3 | Completed | 301 | 2024-04-24 | 2026-10-16 |
Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis Colloidal Silicon Dioxide, Basic Therapy for Atopic Dermatitis - Atopic Dermatitis | Phase 3 | Completed | 161 | 2024-04-10 | 2026-11-10 |
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis Rocatinlimab Prefilled Syringe, Rocatinlimab AI - Atopic Dermatitis | Phase 3 | Completed | 151 | 2024-04-02 | 2026-03-25 |
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis CM310, placebo - Atopic Dermatitis | Phase 3 | Completed | 180 | 2024-03-21 | 2025-10-02 |
A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. LNK01001, Placebo - Atopic Dermatitis | Phase 3 | Completed | 356 | 2024-02-06 | 2026-04-13 |
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis 611, Matching placebo - Dermatitis, Atopic | Phase 3 | Completed | 519 | 2024-01-22 | 2026-01-15 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids Amlitelimab, Placebo, Topical corticosteroids - Dermatitis Atopic | Phase 3 | Completed | 643 | 2024-01-18 | 2026-08-13 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) Amlitelimab, Placebo - Dermatitis Atopic | Phase 3 | Completed | 589 | 2023-12-21 | 2026-08-13 |
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Lebrikizumab - Atopic Dermatitis, Eczema | Phase 3 | Completed | 260 | 2023-11-20 | 2026-07-17 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis Amlitelimab, Placebo - Dermatitis Atopic | Phase 3 | Completed | 601 | 2023-11-08 | 2026-07-22 |
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema Delgocitinib, Vehicle cream - Chronic Hand Eczema | Phase 3 | Completed | 362 | 2023-09-05 | 2025-09-25 |
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy Tralokinumab, Placebo - Atopic Dermatitis, Atopic Hand Eczema | Phase 3 | Completed | 235 | 2023-08-28 | 2026-10-22 |
Showing 20 of 217. Sign in to see all of them.
Narrower conditions
Dermatitis, Atopic (157) · Eczema (56) · Skin Diseases (18) · Radiodermatitis (12) · Breast Neoplasms (9) · Pruritus (9) · Neurodermatitis (8) · Dermatitis, Seborrheic (5) · Hand-Foot Syndrome (5) · Hypersensitivity (5) · Psoriasis (5) · Genetic Diseases, Inborn (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4)
Broader conditions
Skin and Connective Tissue Diseases (217) · Skin Diseases (199) · Skin Diseases, Eczematous (181) · Immune System Diseases (159) · Hypersensitivity (158) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (157) · Genetic Diseases, Inborn (153) · Hypersensitivity, Immediate (153) · Skin Diseases, Genetic (153) · Pathological Conditions, Signs and Symptoms (15) · Wounds and Injuries (12) · Neoplasms (11) · Neoplasms by Site (11) · Radiation Injuries (11)
Interventions
dupilumab (20) · Adrenal Cortex Hormones (13) · lebrikizumab (13) · pimecrolimus (10) · tralokinumab (9) · abrocitinib (8) · Tacrolimus (7) · baricitinib (7) · difamilast (7) · secukinumab (6) · upadacitinib (6) · nemolizumab (4) · Calcineurin Inhibitors (3) · Cyclosporine (3) · Alitretinoin (2)
Sponsors
Eli Lilly and Company (18) · Pfizer (12) · LEO Pharma (10) · Regeneron Pharmaceuticals (10) · Sanofi (10) · Novartis Pharmaceuticals (8) · Amgen (7) · Incyte Corporation (7) · AbbVie (6) · Astellas Pharma Inc (6) · Novartis (5) · Organon and Co (5) · Galderma R&D (4) · Otsuka Pharmaceutical Co., Ltd. (4) · Almirall, S.A. (3)
Countries
United States (103) · Germany (67) · Canada (65) · Poland (57) · France (49) · Spain (47) · Japan (45) · Italy (44) · United Kingdom (44) · South Korea (38) · China (36) · Australia (35) · Hungary (32) · Czechia (30) · Belgium (27)
Top investigators
Diana Villalobos (3) · Osamu Sato (3)
Results publications
PMID 39588375, PMID 42162528, PMID 33826132, PMID 40993471, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 40028832, PMID 31066001, PMID 33165005, PMID 33453450, PMID 34142350, PMID 35636689, PMID 36808602, PMID 39104653, PMID 40555305, PMID 41118053, PMID 31407311, PMID 31424712, PMID 34037993, PMID 34275122, PMID 34688290, PMID 34726270, PMID 34743361, PMID 34897582, PMID 35305260, PMID 35342978, PMID 36152216, PMID 36749121, PMID 38777187, PMID 39110139, PMID 40085349, PMID 40383273, PMID 40457140, PMID 40600584, PMID 41206702, PMID 42365219, PMID 27417017, PMID 27690741, PMID 28503712, PMID 30345457, PMID 30791102, PMID 30972746, PMID 32318744, PMID 32574023, PMID 33000465, PMID 33222559, PMID 33481203, PMID 33658996
NIH funding
2018 (11), 2019 (11), 2017 (8), 2023 (5), 2016 (4), 2015 (2), 2008 (1), 2014 (1), U10CA037420 (1)